1._PD.pdf

Version 11-30-2016-1 FAR Part 11—Describing Agency Needs

PURCHASE DESCRIPTION

1. Statement of Need and Purpose:

NCATS is in need of 1408 small molecules to be included in our Genesis screening libraries. Adding diversity to chemical libraries is imperative to our operation, as we screen a variety of targets against these in-house collections.

2. Background Information and Objective: The National Institutes of Health (NIH) is the nation’s leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people’s health and save lives.

The National Center for Advancing Translational Sciences (NCATS) is a part of the National Institutes of Health (NIH), whose mission it is to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions.

Screening is often the starting point in our development and a wealth of knowledge is obtained from screening a diverse collection. It provides the starting point of all information for medicinal chemistry’s structure-activity relationship (SAR) design to synthesize novel compounds that have more desirable properties. A diverse and novel screening collection provides the backbone of our operation and is imperative for translational sciences to obtain effective small molecules with on-target effects.

These small molecules have been designed around analysis of available chemical and biological information, identification of key pathways modules/targets, computational and “wet biology” assessment of target druggability and potential binding domains. The resulting information is analyzed by synthetic and medicinal chemistry teams in order to bring new chemical diversity and to design unique scaffolds that are likely to interact with the designated targets yielding focused compound libraries. Having such small molecules will make a huge impact in our screening against the variety of targets that NCATS works on and will also help tremendously in bioinformatics analysis which will allow a more thorough and effective SAR expansion by the medicinal chemist.

3. Generic Name of Product: Chemical Library

4. Purchase Description: One (1) Chemical Library of 1408 specific compounds

Salient characteristics:

Vendor is responsible for providing the following:

1. The Contractor must be able to provide the NCATS DPI with 1408 compounds at

3mg each, packaged in NCATS supplied Matrix trubes at 88 compounds per plate.

2. Each small molecule must be guaranteed to have a purity of >90% (accuracy +/-

Version 11-30-2016-1 FAR Part 11—Describing Agency Needs

5%) that is to be confirmed by NMR and/or LCMS spectra

3. In addition to the molecules themselves, the Contractor must be able to provide the following electronic information for each required molecule: chemical structure or simplified molecular-input line-entry system (SMILES) or equivalent chemical structure information, supplier ID, plate ID, well location, tube ID, concentration in millimolar, and volume in microliters. This information shall be provided via email referencing individual compound vial barcodes.

4. The contractor must provide for shipping and handling to send small molecules in the provided vials to the NCATS.

5. Samples will be delivered as 3mg in barcoded tubes provided by NCATS.

5. Quantity: 1 library of 1408 compounds

6. Delivery Date: Delivery to be made within approximately 4-6 weeks after receipt of tubes from NCATS.

7. Period of Performance: This is a one time delivery

8. Option(s): N/A